This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why Is Idexx (IDXX) Down 14.6% Since Last Earnings Report?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
OCPNY vs. IDXX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
OCPNY vs. IDXX: Which Stock Is the Better Value Option?
IDEXX (IDXX) Suffers From Macro Headwinds, Cost Constraints
by Zacks Equity Research
The strengthening of the rate of exchange for the U.S. dollar relative to other currencies has a negative impact on IDEXX's (IDXX) revenues.
IDEXX (IDXX) Q2 Earnings Surpass Estimates, 2022 View Down
by Zacks Equity Research
IDEXX's (IDXX) Q2 top-line benefits from strong sales at the CAG and Water businesses.
Idexx Laboratories (IDXX) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 1.30% and 0.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Quotient (QTNT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Quotient (QTNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OCPNY or IDXX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
OCPNY vs. IDXX: Which Stock Is the Better Value Option?
3 MedTech Stocks That are Likely to Beat This Earnings Season
by Urmimala Biswas
MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how STE, TMO and IDXX are poised ahead of their earnings releases.
IDEXX (IDXX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
IDEXX's (IDXX) Q2 performance will likely benefit from strong sales from the CAG Diagnostics and Water businesses.
Idexx Laboratories (IDXX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Idexx (IDXX) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Are Options Traders Betting on a Big Move in IDEXX Laboratories (IDXX) Stock?
by Zacks Equity Research
Investors need to pay close attention to IDEXX Laboratories (IDXX) stock based on the movements in the options market lately.
Steris (STE) Up 1.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Idexx (IDXX) Up 0.3% Since Last Earnings Report?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
IDEXX's (IDXX) Soft LPD Sales, Margin Pressure Concern
by Zacks Equity Research
Distributor purchasing dynamics have an impact on IDEXX's (IDXX) CAG segment product sales.
Should iShares Russell MidCap Growth ETF (IWP) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWP
IDEXX (IDXX) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Strong sales at the CAG and Water businesses drove IDEXX's (IDXX) first-quarter 2022 revenues.
Idexx Laboratories (IDXX) Q1 Earnings Beat Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 0.89% and 0.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks' Q1 Earnings Due on May 4: CRL, IDXX & NUVA
by Urmimala Biswas
MedTech companies' results are likely to reflect a rebound in the base business. Let's see how CRL, IDXX and NUVA fare this time.
Earnings Preview: Idexx Laboratories (IDXX) Q1 Earnings Expected to Decline
by Zacks Equity Research
Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IDEXX (IDXX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in CAG Diagnostics and Water businesses is likely to have contributed to IDEXX's (IDXX) top line in the first quarter.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
IDEXX (IDXX) CAG Sales Gain Traction, FX Headwind Persists
by Zacks Equity Research
IDEXX (IDXX) has been witnessing continued high CAG Diagnostics recurring revenue growth across major regions with solid gains across its key in-clinic platforms.
Accuray's (ARAY) CyberKnife Effective for Relief From TN Pain
by Zacks Equity Research
Latest data indicates that Accuray's (ARAY) CyberKnife System is effective in providing long-lasting pain relief to patients suffering from TN.